NCT07361471Recruiting
Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy
Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy.
Source: ClinicalTrials.gov · Last updated 20 Feb 2026
Brief summary (registry, in English)
After having constituted the ORTRAI cohort using the CONSORE database at the Jean PERRIN Center, the objective is to characterize the patients both clinically and biologically, histologically and genomically. The clinical and biological characterizations will allow us to confirm that our cohort is comparable with data from the literature. The complement of immunohistochemical and molecular analyses will provide more details on the differences between long-term patients responding to treatment and refractory patients.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 55 (estimated)
- First submitted
- 28 Nov 2025
- Start date
- 22 Jan 2026
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- Centre Jean Perrin
- Diseases
- Ovarian cancer
- NCT number
- NCT07361471
What you commit to
- Study type: Interventional
- Planned participants: 55
- From 22 Jan 2026 to the primary completion date, 1 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Minor patient
- Pregnant patient
- Patient under guardianship or conservatorship
- Patients who object to the collection of their medical/paramedical data
- Patient for whom the center does not have biological material for genomic analysis (FFPE block)
- Patient under administrative, judicial decision or AME (State Medical Aid)
Who the study is looking for
- Major patient, treated at the Jean Perrin Center, suffering from ovarian cancer at any stage and treated with platinum-based chemotherapy in the first line of treatment.
- Corresponding to one of the two groups below:
- Refractory group: patients progressing in the first therapeutic line of platinum-based chemotherapy.
- Group of long-term responders: patients who have not progressed 5 years after the end of first-line platinum salt treatment
- Affiliation to a social security scheme
- Patient who signed the genetic consent form
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Jean Perrin Coordinator of this site? Confirm its status | Clermont-Ferrand | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.